Autopsy report · NCT01094717

Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

“lack of efficacy and lack of funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 1 year 9 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 7 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

Psoriasis

Interventions

Acitretin 25Mg Oral Capsule; Excimer laser; Tazarotene 0.1% Gel,Top; Sham excimer laser

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• Phase II Open-Label Pilot Study of V3381 in Chronic Cough
  “Lack of efficacy” (85% match in meaning)
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
  “Lack of efficacy and enrollment challenges” (80% match in meaning)
• Influence of Esmolol on a Closed-Loop Anesthesia System
  “lack of effectiveness” (76% match in meaning)
• Synbiotics and Post-op Crohn's Disease
  “Lack of funding” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.